BR112022014700A2 - Sars-cov-2 desotimizado e métodos e usos do mesmo - Google Patents

Sars-cov-2 desotimizado e métodos e usos do mesmo

Info

Publication number
BR112022014700A2
BR112022014700A2 BR112022014700A BR112022014700A BR112022014700A2 BR 112022014700 A2 BR112022014700 A2 BR 112022014700A2 BR 112022014700 A BR112022014700 A BR 112022014700A BR 112022014700 A BR112022014700 A BR 112022014700A BR 112022014700 A2 BR112022014700 A2 BR 112022014700A2
Authority
BR
Brazil
Prior art keywords
cov
sars
methods
coronavirus infection
optimized
Prior art date
Application number
BR112022014700A
Other languages
English (en)
Inventor
Mueller Steffen
Robert Coleman John
Wang Ying
Yang Chen
Original Assignee
Codagenix Inc
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codagenix Inc, Serum Institute Of India Pvt Ltd filed Critical Codagenix Inc
Publication of BR112022014700A2 publication Critical patent/BR112022014700A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)

Abstract

SARS-CoV-2 DESOTIMIZADO E MÉTODOS E USOS DO MESMO. São descritos neste documento os coronavírus SARS-CoV-2 modificados. Esses vírus foram recodificados, por exemplo, códons desotimizados ou viés de pares de códons desotimizados e são úteis para reduzir a probabilidade ou a gravidade de uma infecção por coronavírus SARS-CoV-2, prevenir uma infecção por coronavírus SARS-CoV-2, eliciar e resposta imune, ou tratar uma infecção por coronavírus SARS-CoV-2.
BR112022014700A 2020-01-28 2021-01-27 Sars-cov-2 desotimizado e métodos e usos do mesmo BR112022014700A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062966750P 2020-01-28 2020-01-28
US202063048942P 2020-07-07 2020-07-07
US202063079337P 2020-09-16 2020-09-16
US202063079853P 2020-09-17 2020-09-17
PCT/US2021/015246 WO2021154828A1 (en) 2020-01-28 2021-01-27 DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR112022014700A2 true BR112022014700A2 (pt) 2022-10-11

Family

ID=77078567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014700A BR112022014700A2 (pt) 2020-01-28 2021-01-27 Sars-cov-2 desotimizado e métodos e usos do mesmo

Country Status (15)

Country Link
US (1) US20230117167A1 (pt)
EP (1) EP4096712A4 (pt)
JP (1) JP2023519640A (pt)
KR (1) KR20220132588A (pt)
CN (1) CN115427073A (pt)
AU (1) AU2021213121A1 (pt)
BR (1) BR112022014700A2 (pt)
CA (1) CA3168100A1 (pt)
CL (1) CL2022002030A1 (pt)
CO (1) CO2022010743A2 (pt)
IL (1) IL295112A (pt)
MX (1) MX2022009099A (pt)
PE (1) PE20230166A1 (pt)
TW (1) TW202144570A (pt)
WO (1) WO2021154828A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240277830A1 (en) 2020-02-04 2024-08-22 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
AU2021216443A1 (en) * 2020-02-07 2022-09-08 RNAimmune, Inc. Composition and method of mRNA vaccines against novel coronavirus infection
CN115803463A (zh) * 2020-03-06 2023-03-14 基因特力株式会社 用于诊断SARS-CoV-2的组合物、试剂盒以及通过使用所述试剂盒诊断SARS-CoV-2的方法
US20240252616A1 (en) * 2020-07-16 2024-08-01 Griffith University Live-attenuated virus vaccine
KR20230164648A (ko) 2020-12-22 2023-12-04 큐어백 에스이 SARS-CoV-2 변이체에 대한 RNA 백신
WO2023037387A2 (en) 2021-09-08 2023-03-16 Serum Institute Of India Private Limited Freeze-dried viral combination vaccine compositions and process for preparation thereof
AU2022435931A1 (en) * 2022-01-20 2024-07-18 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2023186946A1 (en) * 2022-03-28 2023-10-05 Universität Bern One-to-stop attenuated sars-cov-2 virus
EP4331602A1 (en) * 2022-09-05 2024-03-06 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2024052336A1 (en) 2022-09-05 2024-03-14 Freie Universität Berlin A live attenuated sars-cov-2 and a vaccine made thereof
WO2024079285A1 (en) * 2022-10-12 2024-04-18 Universität Bern Treatment using a one-to-stop attenuated sars-cov-2 virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7339051B2 (en) * 2003-04-28 2008-03-04 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
WO2006042156A2 (en) * 2004-10-08 2006-04-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Modulation of replicative fitness by using less frequently used synonymous codons
US9476032B2 (en) * 2007-03-30 2016-10-25 The Research Foundation For The State University Of New York Attenuated viruses useful for vaccines

Also Published As

Publication number Publication date
MX2022009099A (es) 2022-10-20
TW202144570A (zh) 2021-12-01
JP2023519640A (ja) 2023-05-11
EP4096712A1 (en) 2022-12-07
AU2021213121A1 (en) 2022-08-18
CN115427073A (zh) 2022-12-02
KR20220132588A (ko) 2022-09-30
IL295112A (en) 2022-09-01
US20230117167A1 (en) 2023-04-20
CO2022010743A2 (es) 2022-08-30
CA3168100A1 (en) 2021-08-05
EP4096712A4 (en) 2024-05-08
CL2022002030A1 (es) 2023-03-10
WO2021154828A1 (en) 2021-08-05
PE20230166A1 (es) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022014700A2 (pt) Sars-cov-2 desotimizado e métodos e usos do mesmo
MD3439672T2 (ro) Proteine F RVS de pre-fuziune solubile stabilizate pentru utilizare în profilixia infecţiilor cu RSV
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
BR112022018819A2 (pt) Vacinas contra coronavírus e métodos de uso
BR112022007612A2 (pt) Inibidores de raf quinases
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2020000483A1 (es) Nuevos usos de derivados de piperidinil–indol.
BR112019023758A2 (pt) vírus da doença newcastle e seus usos
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
CL2022003177A1 (es) Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
CL2022002276A1 (es) Composiciones y métodos para tratar discapacidad auditiva no asociada con la edad en un sujeto
MX2024000304A (es) Variantes desoptimizadas de sars-cov-2 y metodos y usos de las mismas.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
CY1125297T1 (el) Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια
EA201991091A1 (ru) Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
CL2022002412A1 (es) Vacuna
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
EA202191543A1 (ru) Способы лечения или профилактики подагры или гиперурикемии
EA202190633A1 (ru) Лекарственные формы для применения в педиатрии, способы получения и применения
BR112022009361A2 (pt) Novas lactonas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso
BR112022005159A2 (pt) Proteína de fusão fc, composição farmacêutica, método de prevenção ou tratamento de um câncer e método para induzir imunidade ou restaurar a capacidade de resposta à imunoterapia
BR112024001911A2 (pt) Vacinas de rna